Patents Assigned to The Rockfeller University
  • SH3 kinase domain associated protein, a signalling domain therein, nucleic acids encoding the protein and the domain, and diagnostic and therapeutic uses thereof
    Patent number: 6022740
    Abstract: The present invention relates to regulation and control of cellular processes by SH3-domain binding proteins, by putative signalling domains of such proteins, ligands of the signalling domain, and diagnosis and therapy based on the activity of such proteins, signalling domains, and ligands.
    Type: Grant
    Filed: December 1, 1994
    Date of Patent: February 8, 2000
    Assignee: The Rockfeller University
    Inventors: Marius Sudol, Peer Bork, Henry Chen
  • Nucleic acid encoding an altered telomere repeat binding factor 2
    Patent number: 6020166
    Abstract: The present invention provides an isolated altered vertebrate telomere repeat binding factor (A-TRFs). Also included are the corresponding nucleic acids that encode the A-TRFs of the present invention, as well as the heterodimers formed by the association of an A-TRF with a TRF. In addition, pharmaceutical compositions containing the A-TRFs for treatment of diseases such as ataxia telangiectasia are also included. Methods of making, purifying and using the A-TRFs of the present invention are described. In addition, drug screening assays to identify drugs that mimic and/or complement the effect of the A-TRFs are presented.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: February 1, 2000
    Assignee: The Rockfeller University
    Inventors: Titia De Lange, Bas Van Steensel, Alessandro Bianchi
  • Antibody recognizing endothelial cell ligand for leukocyte CR3
    Patent number: 6015560
    Abstract: Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: The Rockfeller University
    Inventors: Elaine Tuomanen, H. Robert Masure
  • Method of treating psychosis and/or hyperactivity
    Patent number: 6013621
    Abstract: The present invention discloses the bidirectional regulation of DARPP-32 phosphorylation by dopamine and dopamine D1 and D2 receptors. This disclosure leads to new methodology in the treatment of schizophrenia and related disorders. In addition, the present invention provides methods for identifying agents that can be used in such treatment.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: January 11, 2000
    Assignee: The Rockfeller University
    Inventors: Akinori Nishi, Gretchen L. Snyder, Allen A. Fienberg, Paul Greengard
  • Nucleic acids encoding receptor recognition factors and methods of use thereof
    Patent number: 6013475
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN.alpha. and IFN.gamma..
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: January 11, 2000
    Assignee: The Rockfeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Method of treatment for obsessive-compulsive disorder
    Patent number: 5863734
    Abstract: Methods of identifying patients having a susceptibility to obsessive-compulsive disorder resultant from a reduced level of Catechol-O-methyltransferase (COMT) are described. Therapies, utilizing COMT or COMT agonists, or dopamine antagonists in combination therewith, are also envisioned, as well as methods for determining the patients which will benefit the most from such therapies.
    Type: Grant
    Filed: January 28, 1997
    Date of Patent: January 26, 1999
    Assignee: The Rockfeller University
    Inventors: Maria Karayiorgou, Joseph A. Gogos
  • Afamin: a human serum albumin-like gene
    Patent number: 5652352
    Abstract: The invention relates to a novel human serum protein and nucleic acid referred to as AFM, which has one or more activities in common with human serum albumin, human a-fetoprotein, or human vitamin D binding protein and which has an apparent molecular weight by SDS-PAGE of 87 kd; variants thereof; and related genes, vectors, cells and methods.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: July 29, 1997
    Assignees: Amgen Inc., The Rockfeller University
    Inventors: Henri Stephen Lichenstein, David Edwin Lyons, Mark Matsuo Wurfel, Samuel Donald Wright